WHITEHOUSE STATION, N.J. (AP) — Drugmaker Merck & Co. says it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.
Results from a 25,700-patient study showed that adding Tredaptive to traditional statin therapy did not lower the risk of heart attack, stroke and related problems. Patients taking the cholesterol combination pill were also more likely to suffer serious, non-fatal adverse events. The study compared outcomes for patients taking Tredaptive plus statin drugs, to those taking statins alone.
Tredaptive combines the cholesterol drugs niacin and laropiprant. The drug is sold in about 40 countries, including Europe.
The Food and Drug Administration rejected Tredaptive in 2008 pending more information about the drug's effects on the heart.
Independent voices from the TWT Communities
Covering a real world perspective on the various topics associated with health and addiction issues people want to know about.
Notes from a running nerd: musings and more on all things running.
Wall Street news for retail investors who want to know what's going on.
A collection of reader guest articles, thoughts and opinions by Communities writers and breaking news and information.
World's Ugliest Dog Contest
Spelling Bee finale
Marines train Afghan soldiers
Rolling Thunder 2013
Benghazi: The anatomy of a scandal